Trijardy XR Shortage Update: What Patients Need to Know in 2026

If you're having trouble filling your Trijardy XR prescription, you're likely wondering: is this a real shortage, or is it just my pharmacy? This update explains the current availability situation, why some patients are struggling to find it, and the most practical steps you can take today.

Is Trijardy XR in an Official FDA Shortage?

As of early 2026, Trijardy XR is not listed as an active shortage on the FDA Drug Shortage database. This is important to understand: the FDA only declares a formal shortage when a manufacturer reports they cannot meet national demand. Trijardy XR's manufacturer, Boehringer Ingelheim, has not issued such a declaration.

However, many patients are still encountering out-of-stock situations at individual pharmacies. This points to localized supply and distribution challenges rather than a national shortage — but the practical effect for patients can feel the same.

Why Are Some Patients Having Trouble Finding Trijardy XR?

Several factors have contributed to Trijardy XR availability challenges in 2025 and into 2026:

Surging Demand for Empagliflozin-Containing Products

Empagliflozin — the SGLT2 inhibitor found in both Jardiance and Trijardy XR — has seen its approved uses expand significantly. The FDA approved empagliflozin for heart failure with reduced ejection fraction and, in late 2025, for chronic kidney disease in adults at risk of progression. Each new indication has added millions of potential patients to an already high-demand drug. When supply chains strain for Jardiance, Trijardy XR can experience knock-on effects.

No Generic Competition

Trijardy XR has no generic equivalent as of 2026. Only Boehringer Ingelheim manufactures it. With a single source of supply, any production or distribution delay cannot be absorbed by generic competition — and the full impact falls on patients.

Insurance Formulary Changes in Early 2026

At the start of each year, insurance plans update their formularies. Some plans added or improved coverage for empagliflozin-based products in January 2026, creating a surge of new prescriptions from patients previously on different regimens. This short-term demand spike put pressure on pharmacy distribution networks in the first quarter of the year.

What This Means for You as a Patient

The key takeaway is this: Trijardy XR is being manufactured and is available nationally. The challenge is finding which pharmacies near you have it in stock right now. This is a distribution and inventory challenge, not a production stoppage.

What Should You Do Right Now?

Here's a practical action plan for patients who are having trouble finding Trijardy XR:

1. Check pharmacy availability near you — Use medfinder to find pharmacies in your area that currently have Trijardy XR in stock. medfinder contacts pharmacies and texts you which ones can fill your prescription.
2. Ask your pharmacy to order it — Most pharmacies can receive Trijardy XR through a special order within 1-2 business days.
3. Try independent pharmacies — They often access multiple wholesalers and may have supply when chain pharmacies don't.
4. Contact your prescriber — If you can't find Trijardy XR within a few days, call your doctor's office. They may be able to provide samples, or discuss whether an alternative medication is appropriate temporarily.
5. Never stop diabetes medication abruptly — Discontinuing without medical guidance can cause dangerous blood sugar increases.

When Will Trijardy XR Be Easier to Find?

Availability is expected to stabilize as distribution networks normalize and the initial 2026 formulary-change demand surge subsides. A generic version of the fixed-dose combination is not expected until at least 2027 based on current patent timelines. In the meantime, the strategies above remain your best approach for accessing your medication.

For a full rundown of what patients can take if Trijardy XR is unavailable, see our article on alternatives to Trijardy XR.